Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

被引：4

作者：

Garcia-Manero, Guillermo ^{[1
]}

Platzbecker, Uwe ^{[2
]}

Santini, Valeria ^{[3
]}

Zeidan, Amer M. ^{[4
,5
]}

Fenaux, Pierre ^{[6
]}

Komrokji, Rami S. ^{[7
]}

Shortt, Jake ^{[8
,9
]}

Valcarcel, David ^{[10
]}

Jonasova, Anna ^{[11
]}

Dimicoli-Salazar, Sophie ^{[12
]}

Tiong, Ing Soo ^{[13
]}

Lin, Chien-Chin ^{[14
]}

Li, Jiahui ^{[15
]}

Zhang, Jennie ^{[15
]}

Giuseppi, Ana Carolina ^{[15
]}

Kreitz, Sandra ^{[16
]}

Pozharskaya, Veronika ^{[15
]}

Keeperman, Karen L. ^{[15
]}

Rose, Shelonitda ^{[15
]}

Prebet, Thomas ^{[15
]}

Degulys, Andrius ^{[17
,18
]}

Paolini, Stefania ^{[19
]}

Cluzeau, Thomas ^{[20
]}

Della Porta, Matteo Giovanni ^{[21
,22
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] Univ Leipzig, Med Ctr, Dept Hematol Cellular Therapy Hemostaseol & Infec, Leipzig, Germany

[3] Univ Florence, Azienda Osped Univ Careggi, MDS Unit, DMSC, Florence, Italy

[4] Yale Univ, Yale Sch Med, Dept Internal Med, New Haven, CT USA

[5] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[6] Univ Paris 07, Hop St Louis, Paris, France

[7] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[8] Monash Univ, Melbourne, Australia

[9] Monash Hlth, Melbourne, Australia

[10] Hosp Univ Vall dHebron, Barcelona, Spain

[11] Charles Univ Prague, Gen Univ Hosp, Med Dept Hematol, Prague, Czech Republic

[12] Ctr Hosp Univ Bordeaux, Hop Haut Leveque, Bordeaux, France

[13] The Alfred, Malignant Haematol & Stem Cell Transplantat, Melbourne, Australia

[14] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan

[15] Bristol Myers Squibb, Princeton, NJ USA

[16] Bristol Myers Squibb, Celgene Int Sarl, Boudry, Switzerland

[17] Vilnius Univ Hosp, Santaros Klinikos, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania

[18] Vilnius Univ, Fac Med, Inst Clin Med, Vilnius, Lithuania

[19] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[20] Univ Cote Azur, Dept Hematol Clin, CHU Nice, Nice, France

[21] Canc Ctr IRCCS Humanitas Res Hosp, Milan, Italy

[22] Humanitas Univ, Dept Biomed Sci, Milan, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178596

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 48 条

[31] A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
Santini, V.
Almeida, A.
Giagounidis, A.
Groepper, S.
Jonasova, A.
Vey, N.
Mufti, G. J.
Buckstein, R.
Mittelman, M.
Platzbecker, U.
Shpilberg, O.
Ram, R.
del Canizo, C.
Gattermann, N.
Ozawa, K.
Risueno, A.
MacBeth, K. J.
Zhong, J.
Seguy, F.
Hoenekopp, A.
Beach, C. L.
Fenaux, P.
LEUKEMIA RESEARCH, 2015, 39 : S60 - S61
[32] Multiple periods of transfusion independence (TI) with luspatercept (LUSP) treatment (Tx) and the impact of dose escalation in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS) with ring sideroblasts (RS) from the MEDALIST study
Platzbecker, U.
Santini, V
Komrokji, R. S.
Zeidan, A. M.
Garcia-Manero, G.
Buckstein, R. J.
Oliva, E. N.
Pozharskaya, V
Nadal, J. A.
Miteva, D.
Fenaux, P.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 18 - 19
[33] Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Platzbecker, Uwe
Fenaux, Pierre
Steensma, David P.
Van Eygen, Koen
Raza, Azra
Germing, Ulrich
Font, Patricia
Diez-Campelo, Maria
Thepot, Sylvain
Vellenga, Edo
Patnaik, Mrinal M.
Jang, Jun Ho
Sherman, Laurie
Dougherty, Souria
Sun, Libo
Huang, Fei
Wan, Ying
Rizo, Aleksandra
Berry, Tymara
Feller, Faye
Santini, Valeria
BLOOD, 2020, 136
[34] IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).
Zeidan, Amer Methqal
Platzbecker, Uwe
Santini, Valeria
Fenaux, Pierre
Sekeres, Mikkael A.
Savona, Michael R.
Madanat, Yazan F.
Diez-Campelo, Maria
Valcarcel, David
Illmer, Thomas
Jonasova, Anna
Belohlavkova, Petra
Sherman, Laurie Jill
Berry, Tymara
Dougherty, Souria
Shah, Sheetal
Sun, Libo
Wan, Ying
Huang, Fei
Komrokji, Rami S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[35] Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive
Steensma, David P.
Platzbecker, Uwe
Van Eygen, Koen
Raza, Azra
Santini, Valeria
Germing, Ulrich
Font, Patricia
Samarina, Irina
Diez-Campelo, Maria
Thepot, Sylvain
Vellenga, Edo
Patnaik, Mrinal M.
Jang, Jun Ho
Bussolari, Jacqueline
Sherman, Laurie
Sun, Libo
Varsos, Helen
Rose, Esther
Fenaux, Pierre
BLOOD, 2018, 132
[36] Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US
Mukherjee, Sudipto
Savill, Kristin M.
Gajra, Ajeet
Gentile, Danielle
Falkenstein, Angelica
Miller, Talia
Laney, JaLyna
McBride, Ali
BLOOD, 2022, 140 : 10998 - 11000
[37] Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence ( RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study
Komrokji, Rami S.
Santini, Valeria
Fenaux, Pierre
Savona, Michael R.
Madanat, Yazan F.
Berry, Tymara
Sherman, Laurie
Navada, Shyamala
Feller, Faye M.
Sun, Libo
Xia, Qi
Wan, Ying
Huang, Fei
Zeidan, Amer M.
Platzbecker, Uwe
BLOOD, 2023, 142
[38] Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Santini, Valeria
Almeida, Antonio
Giagounidis, Aristoteles
Groepper, Stefanie
Jonasova, Anna
Vey, Norbert
Mufti, Ghulam J.
Buckstein, Rena
Mittelman, Moshe
Platzbecker, Uwe
Shpilberg, Ofer
Ram, Ron
del Canizo, Consuelo
Gattermann, Norbert
Ozawa, Keiya
Risueno, Alberto
MacBeth, Kyle J.
Zhong, Jianhua
Seguy, Francis
Hoenekopp, Albert
Beach, C. L.
Fenaux, Pierre
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2988 - +
[39] The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions
Della Porta, Matteo
Platzbecker, Uwe
Santini, Valeria
Garcia-Manero, Guillermo
Komrokji, Rami S.
Ito, Rodrigo
Fenaux, Pierre
BLOOD, 2020, 136
[40] Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Platzbecker, Uwe
Steensma, David P.
Van Eygen, Koen
Raza, Azra
Santini, Valeria
Germing, Ulrich
Font, Patricia
Diez-Campelo, Maria
Thepot, Sylvain
Vellenga, Edo
Patnaik, Mrinal M.
Jang, Jun Ho
Sherman, Laurie
Dougherty, Souria
Feller, Faye
Sun, Libo
Wan, Ying
Huang, Fei
Rizo, Aleksandra
Fenaux, Pierre
BLOOD, 2019, 134

← 1 2 3 4 5 →